Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of “Hold” by Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have earned a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $39.45.

Several research analysts have recently commented on TNDM shares. Stifel Nicolaus raised their price target on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup raised their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. SVB Leerink upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $34.00 to $45.00 in a research report on Thursday. Finally, StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $35.56 on Friday. The business has a 50 day simple moving average of $30.74 and a two-hundred day simple moving average of $25.26. Tandem Diabetes Care has a 12 month low of $13.82 and a 12 month high of $40.74. The stock has a market capitalization of $2.30 billion, a P/E ratio of -10.34 and a beta of 1.12. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The company had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. As a group, analysts predict that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of Tandem Diabetes Care by 70.9% during the 3rd quarter. SG Americas Securities LLC now owns 23,510 shares of the medical device company’s stock worth $488,000 after purchasing an additional 9,751 shares during the last quarter. Coronation Fund Managers Ltd. raised its holdings in Tandem Diabetes Care by 70.8% in the 3rd quarter. Coronation Fund Managers Ltd. now owns 354,904 shares of the medical device company’s stock valued at $7,371,000 after acquiring an additional 147,058 shares during the last quarter. Peregrine Capital Management LLC raised its holdings in Tandem Diabetes Care by 27.8% in the 3rd quarter. Peregrine Capital Management LLC now owns 243,355 shares of the medical device company’s stock valued at $5,054,000 after acquiring an additional 52,897 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after acquiring an additional 908 shares during the last quarter. Finally, Raymond James & Associates raised its holdings in Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock valued at $836,000 after acquiring an additional 737 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.